Royalty Pharma (RPRX) EBIT (QoQ) (2019 - 2026)
Royalty Pharma (RPRX) EBIT (QoQ) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -76.36% |
| Mar 31, 2026 | 44.97% |
| Dec 31, 2025 | -9.08% |
| Sep 30, 2025 | 103.60% |
| Jun 30, 2025 | -60.73% |
| Mar 31, 2025 | 47.76% |
| Dec 31, 2024 | -50.82% |
| Sep 30, 2024 | 172.62% |
| Jun 30, 2024 | 465.48% |
| Mar 31, 2024 | -112.04% |
| Dec 31, 2023 | 304.71% |
| Sep 30, 2023 | -39.14% |
| Jun 30, 2023 | -48.05% |
| Mar 31, 2023 | 199.24% |
| Dec 31, 2022 | -351.11% |
| Sep 30, 2022 | -49.12% |
| Jun 30, 2022 | 71.94% |
| Mar 31, 2022 | 43.22% |
| Dec 31, 2021 | -49.38% |
| Sep 30, 2021 | -59.32% |